Literature DB >> 8172207

Clinical documentation of end-stage renal disease due to hypertension.

S D Schlessinger1, M R Tankersley, J J Curtis.   

Abstract

Hypertensive end-stage renal disease (ESRD) purportedly accounts for 25% of new ESRD patients each year in the United States, but remains poorly understood. Clinical features include normal renal function at diagnosis of hypertension, family history of hypertension, left ventricular hypertrophy, and minimal proteinuria. We evaluated clinical and historic data documenting the diagnosis of hypertensive ESRD in 43 patients with ESRD attributed to hypertension who were referred to our center for renal transplantation. Hypertensive ESRD patients were more likely to be black patients with left ventricular hypertrophy compared with our overall population. Few of the hypertensive ESRD patients had undergone kidney biopsy, none of whom had classic features of benign nephrosclerosis. Less than 5% of patients had hypertension documented at any time with normal renal function. Based on our review, it is clearly possible that the number of patients reaching dialysis and transplantation with renal failure attributed to hypertensive ESRD may be overestimated.

Entities:  

Mesh:

Year:  1994        PMID: 8172207     DOI: 10.1016/s0272-6386(12)70275-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  28 in total

Review 1.  Epidemiology of hypertensive kidney disease.

Authors:  Suneel Udani; Ivana Lazich; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2010-11-16       Impact factor: 28.314

Review 2.  Target organ damage in African American hypertension: role of APOL1.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

3.  Risk factors for end-stage renal disease: 25-year follow-up.

Authors:  Chi-yuan Hsu; Carlos Iribarren; Charles E McCulloch; Jeanne Darbinian; Alan S Go
Journal:  Arch Intern Med       Date:  2009-02-23

4.  Impact of high mortality in incident dialysis patients due to hypertensive nephrosclerosis: a multicenter prospective cohort study in Aichi, Japan.

Authors:  Daijo Inaguma; Eri Ito; Kazuo Takahashi; Hiroki Hayashi; Shigehisa Koide; Midori Hasegawa; Yukio Yuzawa
Journal:  Clin Exp Nephrol       Date:  2018-06-07       Impact factor: 2.801

Review 5.  The spectrum of MYH9-associated nephropathy.

Authors:  Meredith A Bostrom; Barry I Freedman
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

6.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

Authors:  Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

7.  Human nephrosclerosis triggers a hypoxia-related glomerulopathy.

Authors:  Matthias A Neusser; Maja T Lindenmeyer; Anton G Moll; Stephan Segerer; Ilka Edenhofer; Kontheari Sen; Daniel P Stiehl; Matthias Kretzler; Hermann-Josef Gröne; Detlef Schlöndorff; Clemens D Cohen
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria.

Authors:  C I Obialo; K Hewan-Lowe
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

Review 9.  Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.

Authors:  J L Pirkle; B I Freedman
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

Review 10.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.